Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Pound firms, lifted by soothing Omicron news, higher gilt yields

Thu, 23rd Dec 2021 11:24

(Updates throughout, adds chart, quotes)

By Sujata Rao

LONDON, Dec 23 (Reuters) - Sterling rose to one-month highs
against the dollar and euro on Thursday, benefiting from some
reassuring reports on the Omicron COVID-19 variant and a move
higher in Britain's short-dated government bond yields.

A three-dose course of AstraZeneca's COVID-19
vaccine is effective against Omicron, the company said, citing
data from an Oxford University study. Its findings match those
from rivals Pfizer-BioNTech and Moderna, which say a third shot
of their vaccines works against Omicron.

Coming on top of reports that Omicron patients are less
likely to need hospitalisation, the news raised hopes that
governments may not need to widen restrictions on activities,
allowing economies to recover.

Britain also cut its COVID-19 self-isolation period to seven
days from 10 days for those who test negative two days in a row.

UK businesses posted the weakest quarterly growth since the
three months to April when lockdowns were in effect, the
Confederation of British Industry (CBI) said.

By 1030 GMT, the pound rose 0.4% to the dollar at $1.3380,
just off a one-month peak of $1.33875 hit earlier.
Against the euro, it firmed to the highest in a month, up 0.4%
to 84.45 pence.

UK gilt yields rose too, outstripping German and U.S. peers,
with 10-year yields up 4.5 basis points and two-year yields
hitting the highest since early November.

Nomura strategist Jordan Rochester noted a pickup in UK
"real" or inflation-adjusted yields. British 5-year real yields
are up some 60 basis points since mid-December. while its U.S.
and German counterparts have flatlined, Refinitiv data shows,

"If you're looking for why sterling remains bid, it's the
continued pickup in real yields," Rochester said, though he
suggested the moves were attributed more to Christmas volumes
"rather than the start of a new uptrend" with the positive
impulse from BOE rate hikes already largely priced in.

Money markets are factoring in 100 basis points of rate
hikes from the BOE in 2022 but Rochester noted headwinds to UK
growth from soaring gas prices and full EU customs controls
kicking in from Jan. 1.

The pound has risen 1.6% to the dollar since Dec. 15, just
before a surprise Bank of England interest rate hike.

Societe Generale analysts said the latest pound gains had
also kicked off as the dollar failed to break above $1.32 on
Wednesday, triggered short-covering.

More positive Omicron news may be needed to fuel further
significant moves, they added.

(Reporting by Sujata Rao; Editing by Catherine Evans and
Bernadette Baum)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.